Menlo Park, CA – Synthekine has announced the appointment of Susan Molineaux as Chief Executive Officer. About Synthekine: Synthekine is a biotechnology company that focuses on discovering, developing, and commercializing the next generation of selective cytokine therapeutics to improve treatment for patients with cancer and autoimmune or inflammatory diseases. From its website, the company describes itself as applying distinct protein engineering platforms and deep immunological insights to design precision immunotherapies that unlock the full efficacy potential of cytokines while minimizing toxicities associated with their broad, pleiotropic activity. It highlights a pipeline of novel immunotherapies including engineered or modified cytokines and surrogate cytokine agonists, built around concepts such as cytokine partial agonism and immunological specificity to selectively modulate key immune pathways. Synthekine positions itself as a leader in cytokines by design , emphasizing rational, structure guided engineering of cytokine therapeutics and presenting itself as a clinical stage company advancing multiple product candidates. The site also presents Synthekine as a company with a broad and deep pipeline, aiming to change standard-of-care treatment paradigms across several disease areas through its specialized cytokine platforms.

For more information visit: https://www.synthekine.com/

Synthekine
1505 O’Brien Drive
Menlo Park, CA 94025
Phone: 650-271-9888
LinkedIn: https://www.linkedin.com/company/synthekine

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved